📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. (2024)

First Author: Goodall RL

Attributed to: Respiratory infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(24)00186-3

PubMed Identifier: 39366400

Publication URI: http://europepmc.org/abstract/MED/39366400

Type: Journal Article/Review

Volume: 12

Parent Publication: The Lancet. Respiratory medicine

Issue: 12

ISSN: 2213-2600